Evidence map›Paper›PMID 30073443›Full record

ReviewHeart failure reviews2019

Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology.

Peggy M Kostakou, Nikos T Kouris, Vassilios S Kostopoulos, Dimitrios S Damaskos, Christoforos D Olympios

Abstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. METTL3 Modulates Radiation-Induced Cardiac Fibrosis via the Akt/mTOR Pathway.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Peggy M KostakouCardiology Department, General Hospital of Elefsina 'Thriassio', Gennimata Ave, 19600, Athens, Greece. pkostakou@gmail.com.
Nikos T KourisCardiology Department, General Hospital of Elefsina 'Thriassio', Gennimata Ave, 19600, Athens, Greece.
Vassilios S KostopoulosCardiology Department, General Hospital of Elefsina 'Thriassio', Gennimata Ave, 19600, Athens, Greece.
Dimitrios S DamaskosCardiology Department, General Hospital of Elefsina 'Thriassio', Gennimata Ave, 19600, Athens, Greece.
Christoforos D OlympiosCardiology Department, General Hospital of Elefsina 'Thriassio', Gennimata Ave, 19600, Athens, Greece.
Thriasio General Hospital of Elefsina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardio-oncology is a new field of interest in cardiology that focuses on the detection, monitoring, and treatment of cardiovascular disease occurring as a side effect of chemotherapy and radiotherapy. Both cancer treatment modalities can cause cardiac dysfunction, a major cause of morbidity and mortality in the oncologic population. It is necessary to periodically monitor cancer patients under treatment, especially those receiving anthracyclines and trastuzumab (monoclonal antibody), using mainly 3D echocardiography to calculate left ventricular ejection fraction and to estimate myocardial deformation. Additionally, measuring various biomarkers, such as natriuretic peptides, could facilitate early identification and appropriate response to potential cardiotoxicity. In this regard, cardiological assessment before starting cancer treatment is essential and should be continued throughout, since cardiac dysfunction can occur at any time, even several years after therapy onset. High-risk individuals, in particular, should receive a detailed management plan designed in collaboration between an oncology and a cardiology specialist. If heart failure develops, even in the absence of overt clinical symptoms, standard heart treatment is to be followed and causal agent discontinued if possible. One important question is whether and when to stop cardiac medication in case of heart dysfunction reversal, after completion of cancer treatment. Further cardio-oncology evolution can lead to a deeper understanding of the adverse mechanisms and effects causing heart failure, as well as the development of personalized treatment regimens in order to limit cardiotoxicity.

Indexed as

AgedAged, 80 and overAnthracyclinesAntineoplastic AgentsCardiologyCardiotoxicityChemoradiotherapyHeart DiseasesHumansMiddle AgedNeoplasmsRadiation DosageRisk FactorsTrastuzumabAnthracyclinesAntineoplastic AgentsTrastuzumabCancerCardiotoxicityEchocardiographyHeart failureStrain

Identifiers

PMID30073443
OpenAlexW2885900087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.